Ovid Therapeutics (OVID)
(Delayed Data from NSDQ)
$0.87 USD
+0.04 (5.31%)
Updated Jul 10, 2024 04:00 PM ET
After-Market: $0.89 +0.02 (1.83%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
OVID 0.87 +0.04(5.31%)
Will OVID be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for OVID based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for OVID
Biotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
OVID Slumps 76% on Epilepsy Drug Failing Two Pivotal Studies
OVID: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates
Alimera Sciences (ALIM) Reports Q1 Loss, Misses Revenue Estimates
Adma Biologics (ADMA) Surpasses Q1 Earnings and Revenue Estimates
Other News for OVID
eNeuro Publishes Findings on the Anti-Convulsant Properties of OV329 and Its Potential Effectiveness in Treatment-Resistant Seizures
Ovid Therapeutics Announces Workforce Reduction to Extend Runway
Catalyst Watch: Tesla deliveries, Constellation Brands earnings, and the June Jobs Report
Biotech Alert: Searches spiking for these stocks today
Biotech Alert: Searches spiking for these stocks today